To Assess Feasibility of the New ApplicationFattyPancreasNCT07255989
Diagnosis of Fatty Pancreas by FibroScan
A study testing meeting about the nutrition in people with To Assess Feasibility of the New Application, run by Benha University at 1 site in Egypt.
Trial summary
Example 2: Interventional study The goal of this observational study is to learn know about the use of FibroScan in diagnosis of fatty pancreas in obese and non obese patients which done for the first time at worldwide as well as Egypt .The participtants already came to do liver FibroScan at center of excellence … Read more about this study
- Who is it for?
- Ages 20 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- To Assess Feasibility of the New Application
- What is being tested?
- meeting about the nutrition
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteEgypt
- Study dates
- 19 Apr 2023to 5 May 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Subjects aged from 30 to 70 years old , both male and females , DM or not obese or non obese
Who cannot join
- Subjects with significant amount of alcohol consumption or history of alcohol consumption (>60 g/day).
- History of steatogenic medications (amiodarone, valproic acid, corticosteroids, tetracyclines).
- Patients with a previous history of pancreatic disease
- -
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Study About the Role of Gut Microbiome in Fatty Liver -Fatty Pancreas and Heart Diseases .
Example 2: Interventional study The goal of this observational study is to learn know about the use of FibroScan in diagnosis of fatty pancreas in obese and non obese patients which done for the first time at worldwide as well as Egypt .The participtants already came to do liver FibroScan at center of excellence , Benha University , Egypt. Untill now the diagnosis of fatty pancreas by MRI which accurate and specific and diagnose fatty pancreasif it is more than 6.2% . lough the use of abdominal ultrasound also is proved . The use of digital fibroscan which is easy non invasive , unique as well as we can diagnose fibrosis too in the same sitting .So it is highly recommended to be add with examination of liver by fibroscan.
Read the detailed description
This Interventional study done for subjects attend Center of excellence , at Benha University . aged of patients was from 30 years to 70 years old , both male and females , obese or non and DM or non . the patients came to do fibroscan to liver . Lab investigations in the form of CBC ,ESR , liver function tests , kidney function tests. Complete lipid profile , HbA1c .clincal and physical examinations done as regard BMI, past history for metabolic diseases , operations and blood transfusion. FibroScan done first to liver while the patients fastinf at least 3 hours with the know specific position recommendation (banana like ).The position for pancreas examination by fibroScan differe as the patient dorsal position/ recumbancy and his hand behind his head . take deep breah and slighlty keep it . some tilting to the left or right . the probe of fibroscan in the epigastrium under the left rib.which totally differe than liver which in the RT anterior axillary line 8 th intercostal space.picture taken , the unique , novality of this modility is the diagnosis of fibrosis too like liver.Grading of aftty pancreas was done as well as fibrosis of pancreas as follow :S1 =264 dB/m , S2 =276 dB/m and S3 =336 dB/m .
- Being tested
- meeting about the nutrition
- Keywords
- Fatty Pancreas , FibroScan
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
meeting about the nutritionDevice
In the meeting time abou the nutrition we talk about our ancient egyptian food which confirmed with Carton already present at center of excellence ,
| Study group | Role | What they receive |
|---|---|---|
| the patients evaluated clinically , physically and interview after that examination done by Fibr | Experimental | Not described Receives: Device: meeting about the nutrition |
What is being measured
The primary outcome is the main question the study is designed to answer.
prevelance of fatty pancreas 60% which is more common than the expection
the need to raise uo the importance to use FibroScan to diagnosis of fatty pancreas which is novel , unique and invasive , specific
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Dec 2025
- Study start19 Apr 2023
- Primary completion19 Apr 2024
- Study completion5 May 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for To Assess Feasibility of the New ApplicationStudies of the same condition, open and under way.
- More trials run by Benha UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Evaluation of uses FibroScan as non invasive method for diagnosis of fatty pancreas
- Masking
- None (open label)
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Benha University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Prof.Reda Mohamed Elbadawy, Benha University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07255989
- Sponsor's protocol ID
- CEPHENo5145,2022,BU.
- Other IDs
- Ministry of Higher education
- Acronym
- FattyPancreas
- Status last verified
- Nov 2025
- First submitted
- 17 Nov 2025
- Last updated
- 1 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: because the property of the technique
Study at a glance
From the registry record, last updated by the sponsor on 1 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study About the Role of Gut Microbiome in Fatty Liver -Fatty Pancreas and Heart Diseases .
- ClinicalTrials.gov ID
- NCT07255989
- Acronym / sponsor ID
- FattyPancreas / CEPHENo5145,2022,BU.
- Keywords
- Fatty Pancreas , FibroScan
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Benha UniversityUniversity, hospital or other
- Study start
- 19 Apr 2023 (actual)
- Primary completion
- 19 Apr 2024 (actual)
- Study completion
- 5 May 2024 (actual)
- First posted
- 1 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Example 2: Interventional study The goal of this observational study is to learn know about the use of FibroScan in diagnosis of fatty pancreas in obese and non obese patients which done for the first time at worldwide as well as Egypt .The participtants already came to do liver FibroScan at center of excellence , Benha University , Egypt. Untill now the diagnosis of fatty pancreas by MRI which accurate and specific and diagnose fatty pancreasif it is more than 6.2% . lough the use of abdominal ultrasound also is proved . The use of digital fibroscan which is easy non invasive , unique as well as we can diagnose fibrosis too in the same sitting .So it is highly recommended to be add with examination of liver by fibroscan.
Detailed description
This Interventional study done for subjects attend Center of excellence , at Benha University . aged of patients was from 30 years to 70 years old , both male and females , obese or non and DM or non . the patients came to do fibroscan to liver . Lab investigations in the form of CBC ,ESR , liver function tests , kidney function tests. Complete lipid profile , HbA1c .clincal and physical examinations done as regard BMI, past history for metabolic diseases , operations and blood transfusion. FibroScan done first to liver while the patients fastinf at least 3 hours with the know specific position recommendation (banana like ).The position for pancreas examination by fibroScan differe as the patient dorsal position/ recumbancy and his hand behind his head . take deep breah and slighlty keep it . some tilting to the left or right . the probe of fibroscan in the epigastrium under the left rib.which totally differe than liver which in the RT anterior axillary line 8 th intercostal space.picture taken , the unique , novality of this modility is the diagnosis of fibrosis too like liver.Grading of aftty pancreas was done as well as fibrosis of pancreas as follow :S1 =264 dB/m , S2 =276 dB/m and S3 =336 dB/m .
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Evaluation of uses FibroScan as non invasive method for diagnosis of fatty pancreas
| Arm | Type | Receives |
|---|---|---|
| the patients evaluated clinically , physically and interview after that examination done by Fibr | Experimental | Device: meeting about the nutrition |
Who may qualify
- Ages
- 20 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Subjects aged from 30 to 70 years old , both male and females , DM or not obese or non obese
Key exclusion criteria (4 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| meeting about the nutritionIn the meeting time abou the nutrition we talk about our ancient egyptian food which confirmed with Carton already present at center of excellence , | Device | the patients evaluated clinically , physically and interview after that examination done by Fibr |
Primary outcome
prevelance of fatty pancreas 60% which is more common than the expection
Time frame: 6 months
the need to raise uo the importance to use FibroScan to diagnosis of fatty pancreas which is novel , unique and invasive , specific
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Dec 2025.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No. because the property of the technique
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing meeting about the nutrition in people with To Assess Feasibility of the New Application, run by Benha University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
prevelance of fatty pancreas 60% which is more common than the expection (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Dec 2025.